Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants
Early pharmacological treatment for hemodynamically significant patent ductus arteriosus (hs-PDA) in preterm infants shows little to no difference in mortality or major morbidities like chronic lung disease. While it increases pharmacotherapy, it only trivially reduces invasive closure. Ibuprofen's very early use may even increase mortality in extremely preterm infants.
Patent ductus arteriosus (PDA) is associated with significant morbidity and mortality in preterm infants. Cyclo‐oxygenase (COX) inhibitor drugs are used to prevent or treat a PDA. There are concerns regarding the adverse effects of COX inhibitors in preterm infants. Controversy exists about whether early targeted treatment of a hemodynamically significant (hs)‐PDA improves clinical outcomes.
Click here to access the article.